[ad_1]
The Food and Drug Administration has approved the injection of Eli Lilly (NYSE: LLY) for the preventive treatment of migraine in adults, one of three drugs in a new class recently approved for migraines.
LLY has announced its intention to sell the drug, known as chemical galcanezumab, at a price of $ 6,900 a year, or $ 575 a month, identical to other new migraine treatments, Aimovig's Amgen ( NASDAQ: AMGN) and Novartis. (NYSE: NVS), and Teva (NYSE: TEVA) Ajovy.
LLY stated that the efficacy and safety of Emgality have been demonstrated in two Phase 3 clinical trials in patients with episodic migraine and a Phase 3 clinical trial in migraine patients chronic.
According to the Migraine Research Foundation, some 39 million Americans suffer from migraines.
[ad_2]
Source link
